INmune Bio (INMB) Revenue & Revenue Breakdown
INmune Bio Revenue Highlights
Latest Revenue (Y)
$-155.00K
INmune Bio Revenue by Period
INmune Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $-155.00K | -141.44% |
| 2022-12-31 | $374.00K | 106.63% |
| 2021-12-31 | $181.00K | 1558.12% |
| 2020-12-31 | $10.92K | -99.99% |
| 2019-12-31 | $77.69M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
INmune Bio generated $-155.00K in revenue during NA 2023, up -141.44% compared to the previous quarter, and up -Infinity% compared to the same period a year ago.
INmune Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $14.00K | -50.00% |
| 2023-12-31 | $28.00K | -34.88% |
| 2023-09-30 | $43.00K | -6.52% |
| 2023-06-30 | $46.00K | 21.05% |
| 2023-03-31 | $38.00K | -60.82% |
| 2022-12-31 | $97.00K | -1.02% |
| 2022-09-30 | $98.00K | 512.50% |
| 2022-06-30 | $16.00K | -90.18% |
| 2022-03-31 | $163.00K | - |
| 2021-12-31 | $163.00K | 1064.29% |
| 2021-09-30 | $14.00K | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $4.00K | -63.36% |
| 2020-12-31 | $10.92K | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $77.69M | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | - |
INmune Bio generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
INmune Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TCRX | TScan Therapeutics | $21.05M | - |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| ANIX | Anixa Biosciences | $210.00K | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| ANTX | AN2 Therapeutics | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| DBTX | Decibel Therapeutics | - | - |
| BIVI | BioVie | - | - |
| INAB | IN8bio | - | - |
| SAVA | Cassava Sciences | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| DRMA | Dermata Therapeutics | - | - |
| PYPD | PolyPid | - | - |
| AVXL | Anavex Life Sciences | - | - |
| INMB | INmune Bio | $-155.00K | - |
INMB Revenue FAQ
What is INmune Bio’s yearly revenue?
INmune Bio's yearly revenue for 2023 was $-155K, representing a decrease of -141.44% compared to 2022. The company's yearly revenue for 2022 was $374K, representing an increase of 106.63% compared to 2021. INMB's yearly revenue for 2021 was $181K, representing an increase of 1558.12% compared to 2020.
What is INmune Bio’s quarterly revenue?
INmune Bio's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $14K, a -50.00% decrease from the previous quarter (Q4 2023), and a -63.16% decrease year-over-year (Q1 2023). INMB's quarterly revenue for Q4 2023 was $28K, a -34.88% decrease from the previous quarter (Q3 2023), and a -71.13% decrease year-over-year (Q4 2022).
What is INmune Bio’s revenue growth rate?
INmune Bio's revenue growth rate for the last 3 years (2021-2023) was -185.64%, and for the last 5 years (2019-2023) was -100.20%.